The cancer therapeutics sector in the Netherlands is fast-growing and continuously evolving, fueled by breakthroughs in research, technology, and a strong healthcare infrastructure. The Dutch Cancer Society actively funds research and supports programs aimed at enhancing cancer treatment and patient outcomes. In September 2024, the Dutch Research Council (NWO) allocated US$ 27.8 million (25 million euros) to tackle the rising challenges in cancer care. With the number of cancer patients projected to increase from 800,000 in 2022 to 1.4 million by 2031, this funding supports research into cutting-edge imaging technologies, the integration of oncology and neurology, and partnerships between public institutions, private companies, and knowledge centers to drive healthcare advancements. Also in September 2024, Curium, a global leader in nuclear medicine, inaugurated a new production facility in Petten to manufacture non-carrier-added lutetium-177 (Lu-177). This isotope plays a critical role in cancer treatment, offering patients therapies with reduced side effects, better quality of life post-treatment, and slower disease progression.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook